In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmaKodex Ltd.

Division of Orexo AB
www.pharmakodex.com

Latest From PharmaKodex Ltd.

PharmaKodex Ltd.

PharmaKodex, a joint venture of Vectura Group and Unilever Ventures, is developing oral and dermal delivery systems that improve availability, thus improving drug response time and activity, leading to greater patient acceptance. The company is adding a twist to the standard low-risk reformulation model now ubiquitous in the specialty pharma world; it intends to use its technologies to develop OTC drugs that will hit market faster and bring in revenue to fund prescription drug development.
BioPharmaceutical Consumer

Macromolecules & Spec Pharma: The Good News in Drug Delivery

Two major changes have transformed the prospects for drug-delivery companies: the rise of spec pharma and Big Pharma's embrace of large-molecule therapeutics. A new group of start-ups represents strategies to take advantage of both opportunities.
BioPharmaceutical Business Strategies

PharmaKodex Ltd.

PharmaKodex, a joint venture of Vectura Group and Unilever Ventures, is developing oral and dermal delivery systems that improve availability, thus improving drug response time and activity, leading to greater patient acceptance. The company is adding a twist to the standard low-risk reformulation model now ubiquitous in the specialty pharma world; it intends to use its technologies to develop OTC drugs that will hit market faster and bring in revenue to fund prescription drug development.
BioPharmaceutical Consumer

Drug Delivery Spin-Off Adds OTC

Vectura, focused on pulmonary drug delivery, has created a spin off which assembles the oral and dermal technologies it had already de-prioritized, with two enabling technologies from Unilever. PharmaKodex Ltd. will develop OTC drugs as a fast route to market, followed by Rx products using the same technologies.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
    • OTC, Consumer
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Orexo AB
  • Senior Management
  • Rod Richards, CEO
    Keith Churchman, CFO
    John Staniforth, CSO
  • Contact Info
  • PharmaKodex Ltd.
    Phone: (44) 0 1223 421601
    St. John's Innovation Centre
    Cowley Rd.
    Cambridge, CB4 OWS
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register